CAR-T: Continuation in a Revolution of Cancer Therapeutics

CAR-T: Continuation in a Revolution of Cancer Therapeutics was first presented at the Kansas Association of Osteopathic Medicine Annual Conference 2023. This program now made available on-demand follows Joseph McGuirk, DO, as he explains the CAR-T Cell Therapy program.

Learning Objectives:

1. Understand the importance of immunotherapy in current cancer treatment.
2. Recognize appropriate patient for CAR-T therapy approval.
3. Understand historic outcomes in patients with blood cancers not responding to chemotherapy.

Accreditation Statement:

KAOM is an accredited sponsor by the American Osteopathic Association for osteopathic continuing medical education for physicians. KAOM designates this program for a maximum of 1 AOA Category 1-A CME credits and will report CME and specialty credits commensurate with the physician’s participation. 

KAOM Grievance Policy:

KAOM strives to provide medical education programs that fulfill the needs of the attendees. Comments, questions, or complaints should be submitted in writing to Kemper Tell, Executive Director at P.O. Box 4368 Topeka, KS 66604 or kemper@kansasdo.org. 

Faculty Disclosure Declaration:

Joseph McGuirk, DO, has disclosed consultant connections with Envision, Kite, AlloVir, BMS, Novartis, Nektar, Sana, Caribou Bio, Legend Biotech.